Mammalian target of rapamycin inhibition in macrophages of asymptomatic HIV+ persons reverses the decrease in

Xin Li1, Xinbing Han, Juliana Llano

  • 1Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

Insights

Impaired Toll-like receptor 4 (TLR-4) signaling in HIV(+) macrophages involves mammalian target of rapamycin (mTOR) activation. Inhibiting mTOR enhances TNF-α release, potentially restoring innate immune defense.

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • Toll-like receptor 4 (TLR-4) signaling is crucial for innate immunity but is impaired in macrophages from individuals with HIV.
  • This impairment is linked to the MyD88-dependent pathway and constitutive activation of phosphoinositide 3-kinase (PI3K).

Purpose of the Study:

  • To investigate the association between PI3K-induced mammalian target of rapamycin (mTOR) activity and blunted TLR-4-mediated TNF-α release in HIV(+) macrophages.
  • To explore the therapeutic potential of mTOR inhibition in restoring macrophage immune function.

Main Methods:

  • Macrophages from HIV(+) individuals were treated with lipid A (LA) to stimulate TLR-4.
  • Intervention with rapamycin (mTOR inhibitor) or gene silencing of mTOR and MyD88 was employed.
  • Analysis included TNF-α and IL-10 release, MyD88/IL-1R-associated kinase interaction, S6 kinase activation, and MAPK phosphorylation (ERK1/2, JNK1/2) and MKP-1 stability.

Main Results:

  • mTOR inhibition enhanced TLR-4-mediated TNF-α release while suppressing IL-10 release.
  • Gene silencing of mTOR mimicked rapamycin's effects on cytokine release.
  • mTOR inhibition restored MyD88/IL-1R-associated kinase interaction and augmented TNF-α release via enhanced MAPK activation and MKP-1 destabilization.

Conclusions:

  • Impaired TLR-4-mediated TNF-α release in HIV(+) macrophages is partly due to mTOR activation via PI3K in a MyD88-dependent pathway.
  • This pathway leads to MAPK phosphatase 1 stabilization, reducing MAPK activation.
  • mTOR inhibition presents a potential therapeutic strategy to enhance macrophage innate immune responses in HIV(+) individuals.